Disclosed are novel immunogenic proteins derived from Staphylococcus aureus, as well as methods for their use in conferring protective immunity against S. aureus infections. Also disclosed are nucleic acids encoding the proteins and methods of use of these nucleic acids.

Provided herein is a method of treating or preventing a disease or disorder (e.g., MS) in a subject in need thereof, comprising (a) administering to the subject a first dose of a pharmaceutical composition comprising a fumarate agent (e.g., DMF) for a first dosing period; (b) administering a vaccine; and (c) administering to the subject a second dose of the pharmaceutical composition for a second dosing period.

The present disclosure provides methods for enhancing the immunogenicity of a poorly immunogenic antigen-specific vaccine as well as methods for promoting diversification of the gut microbiome in a subject in need thereof comprising administering to the subject an effective amount of a beta-glucan extract derived from yeast. Kits for use in practicing the methods are also provided.

Disclosed herein is a vaccine composition for raising a humoral response to PD1, and uses thereof, for treating a cancer characterised by an involvement of PD1, wherein the vaccine composition comprises an effective amount of an immunogen that induces an antibody response in which the antibody binds to a B cell epitope of PD1.

Provided are methods for preventing initiation and/or progression of gastrin-associated tumors and/or cancers in subjects. In some embodiments, the methods relate to administering compositions that gastrin immunogens to subjects. Also provided are methods for inhibiting development of gastrin-associated precancerous lesions, methods for preventing formation of fibrosis associated with a tumor and/or a cancer, uses of compositions that include a gastrin immunogen to prevent initiation and/or development of a gastrin-associated tumor or cancer and/or for preparing medicaments therefor, and compositions for use in preventing initiation and/or development of gastrin-associated tumors and/or cancers and/or precancerous lesions thereof.

In a fluoro-TF-MUC1 glycopeptide conjugate, a glycopeptide has a clear and single chemical structure, and can be synthesized in large quantities by chemical methods. The linker selected is easy to be activated, which can be coupled with a carrier protein with high efficiency, and improve the glycoprotein load of the carrier protein. The introduction of fluorine atoms can enhance the stability of glycosidic bonds in glycopeptide antigens, thereby improving the metabolic stability, fat solubility and bioavailability of glycopeptide antigens, and solving the problems of poor immunogenicity and instability of natural tumor-associated MUC1 glycopeptide. Enzyme-linked immunoassay (ELISA) shows that the antibodies in the serum after immunization can recognize the natural MUC1 and achieve cross recognition.

The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.

The disclosure pertains to N-terminal epitopes identified in A-beta, including conformational epitopes, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.

Compositions that include an albumin binding domain and a fusion partner (e.g., a cytokine or a binding moiety) are provided. Such therapeutics have increased serum half-life and find use in applications where one or more such therapeutics are needed, for example, in oncology applications.

The present disclosure provides vaccines or immunogenic compositions against clinical signs, symptoms, and losses attributable to or caused by infection with PEDV and/or ETEC. Antigenic epitopes from PEDV and ETEC are used to construct an immunogenic composition, preferably in the form of a multi-epitope fusion antigen or as a live strain through E. coli.